ReviewFrontiers in bioengineering and biotechnology2020
Engineering Targeting Materials for Therapeutic Cancer Vaccines.
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Cancer mRNA vaccines: clinical advances and future opportunities.Nature reviews. Clinical oncology · 2024Review
- Personalized mRNA vaccine combined with PD-1 inhibitor therapy in a patient with advanced esophageal squamous cell carcinoma.American journal of cancer research · 2024Article
- Engineered Probiotic-Based Personalized Cancer Vaccine Potentiates Antitumor Immunity through Initiating Trained Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Review
- Membrane-localized neoantigens predict the efficacy of cancer immunotherapy.Cell reports. Medicine · 2023Article
- The heterocellular heart: identities, interactions, and implications for cardiology.Basic research in cardiology · 2023Review
- Recent advancements in single dose slow-release devices for prophylactic vaccines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer.International journal of molecular sciences · 2022Review
- Insights into intercellular receptor-ligand binding kinetics in cell communication.Frontiers in bioengineering and biotechnology · 2022Review
- Targeting the Extracellular Matrix in Traumatic Brain Injury Increases Signal Generation from an Activity-Based Nanosensor.ACS nano · 2021Article
- Traceable metallic antigen release for enhanced cancer immunotherapy.Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2021Article
- Review
- Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations.World journal of gastroenterology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Therapeutic cancer vaccines constitute a valuable tool to educate the immune system to fight tumors and prevent cancer relapse. Nevertheless, the number of cancer vaccines in the clinic remains very limited to date, highlighting the need for further technology development. Recently, cancer vaccines have been improved by the use of materials, which can strongly enhance their intrinsic properties and biodistribution profile. Moreover, vaccine efficacy and safety can be substantially modulated through selection of the site at which they are delivered, which fosters the engineering of materials capable of targeting cancer vaccines to specific relevant sites, such as within the tumor or within lymphoid organs, to further optimize their immunotherapeutic effects. In this review, we aim to give the reader an overview of principles and current strategies to engineer therapeutic cancer vaccines, with a particular focus on the use of site-specific targeting materials. We will first recall the goal of therapeutic cancer vaccination and the type of immune responses sought upon vaccination, before detailing key components of cancer vaccines. We will then present how materials can be engineered to enhance the vaccine's pharmacokinetic and pharmacodynamic properties. Finally, we will discuss the rationale for site-specific targeting of cancer vaccines and provide examples of current targeting technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.